Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
8
×
cancer
8
×
life sciences
national blog main
clinical trials
cancer drugs
national top stories
san francisco blog main
ipo
new york blog main
san francisco top stories
boston
europe blog main
fda
sanofi
third rock ventures
blueprint medicines
drug discovery
eli lilly
europe top stories
indiana blog main
indiana top stories
investing
new york top stories
non-small cell lung cancer
novartis
revolution medicines
roche
san francisco
startups
the column group
venture capital
warp drive bio
accent therapeutics
adeno-associated virus
aducanumab
agios pharmaceuticals
alzheimer's disease
What
medicines
8
×
ipo
cancer
drug
new
research
fda
pipeline
proteins
revolution
targets
therapeutics
activity
adding
address
ago
aiming
approval
approvals
approves
balance
based
begin
bio
biogen
biosciences
biotech
bio’s
black
blueprint
brings
bubbles
build
cancer’s
carries
cells
certain
clamped
class
clinic
Language
unset
8
×
Current search:
medicines
×
cancer
×
" boston top stories "
×
unset
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic